Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia

Tadeusz Robak; Anna Dmoszynska; Philippe Solal-Céligny; Krzysztof Warzocha; Javier Loscertales; John Catalano; Boris V Afanasiev; Loree Larratt; Christian H Geisler; Marco Montillo; Ilya Zyuzgin; Peter S Ganly; Caroline Dartigeas; András Rosta; Jörg Maurer; Myriam Mendila; M Wayne Saville; Nancy Valente; Michael K Wenger; Sergey I Moiseev

doi:10.1200/JCO.2009.26.4556

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia

Tadeusz Robak, Anna Dmoszynska, Philippe Solal-Céligny, Krzysztof Warzocha, Javier Loscertales, John Catalano, Boris V Afanasiev, Loree Larratt, Christian H Geisler, Marco Montillo, Ilya Zyuzgin, Peter S Ganly, Caroline Dartigeas, András Rosta, Jörg Maurer, Myriam Mendila, M Wayne Saville, Nancy Valente, Michael K Wenger, Sergey I Moiseev

453 Citationer (Scopus)

Abstract

Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered alone or in combination with chemotherapy. Promising results have previously been reported in nonrandomized studies in patients with chronic lymphocytic leukemia (CLL). This trial was designed to compare chemoimmunotherapy with chemotherapy alone in patients with previously treated CLL.

Originalsprog	Engelsk
Tidsskrift	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Vol/bind	28
Udgave nummer	10
Sider (fra-til)	1756-65
Antal sider	10
DOI	https://doi.org/10.1200/JCO.2009.26.4556
Status	Udgivet - 1 apr. 2010

Adgang til dokumentet

10.1200/JCO.2009.26.4556

Andre filer og links

Link to publication in Scopus

Citationsformater

Robak, T., Dmoszynska, A., Solal-Céligny, P., Warzocha, K., Loscertales, J., Catalano, J., Afanasiev, B. V., Larratt, L., Geisler, C. H., Montillo, M., Zyuzgin, I., Ganly, P. S., Dartigeas, C., Rosta, A., Maurer, J., Mendila, M., Saville, M. W., Valente, N., Wenger, M. K., & Moiseev, S. I. (2010). Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(10), 1756-65. https://doi.org/10.1200/JCO.2009.26.4556

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. / Robak, Tadeusz; Dmoszynska, Anna; Solal-Céligny, Philippe et al.
I: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Bind 28, Nr. 10, 01.04.2010, s. 1756-65.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Robak, T, Dmoszynska, A, Solal-Céligny, P, Warzocha, K, Loscertales, J, Catalano, J, Afanasiev, BV, Larratt, L, Geisler, CH, Montillo, M, Zyuzgin, I, Ganly, PS, Dartigeas, C, Rosta, A, Maurer, J, Mendila, M, Saville, MW, Valente, N, Wenger, MK & Moiseev, SI 2010, 'Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, bind 28, nr. 10, s. 1756-65. https://doi.org/10.1200/JCO.2009.26.4556

Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 apr. 1;28(10):1756-65. doi: 10.1200/JCO.2009.26.4556

Robak, Tadeusz ; Dmoszynska, Anna ; Solal-Céligny, Philippe et al. / Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. I: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 ; Bind 28, Nr. 10. s. 1756-65.

@article{e81a99ba83d4498ab3fc25300de00691,

title = "Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia",

abstract = "Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered alone or in combination with chemotherapy. Promising results have previously been reported in nonrandomized studies in patients with chronic lymphocytic leukemia (CLL). This trial was designed to compare chemoimmunotherapy with chemotherapy alone in patients with previously treated CLL.",

author = "Tadeusz Robak and Anna Dmoszynska and Philippe Solal-C{\'e}ligny and Krzysztof Warzocha and Javier Loscertales and John Catalano and Afanasiev, \{Boris V\} and Loree Larratt and Geisler, \{Christian H\} and Marco Montillo and Ilya Zyuzgin and Ganly, \{Peter S\} and Caroline Dartigeas and Andr{\'a}s Rosta and J{\"o}rg Maurer and Myriam Mendila and Saville, \{M Wayne\} and Nancy Valente and Wenger, \{Michael K\} and Moiseev, \{Sergey I\}",

year = "2010",

month = apr,

day = "1",

doi = "10.1200/JCO.2009.26.4556",

language = "English",

volume = "28",

pages = "1756--65",

journal = "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia

AU - Robak, Tadeusz

AU - Dmoszynska, Anna

AU - Solal-Céligny, Philippe

AU - Warzocha, Krzysztof

AU - Loscertales, Javier

AU - Catalano, John

AU - Afanasiev, Boris V

AU - Larratt, Loree

AU - Geisler, Christian H

AU - Montillo, Marco

AU - Zyuzgin, Ilya

AU - Ganly, Peter S

AU - Dartigeas, Caroline

AU - Rosta, András

AU - Maurer, Jörg

AU - Mendila, Myriam

AU - Saville, M Wayne

AU - Valente, Nancy

AU - Wenger, Michael K

AU - Moiseev, Sergey I

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered alone or in combination with chemotherapy. Promising results have previously been reported in nonrandomized studies in patients with chronic lymphocytic leukemia (CLL). This trial was designed to compare chemoimmunotherapy with chemotherapy alone in patients with previously treated CLL.

AB - Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, has clinical activity in patients with non-Hodgkin's lymphoma and other B-lymphocyte disorders when administered alone or in combination with chemotherapy. Promising results have previously been reported in nonrandomized studies in patients with chronic lymphocytic leukemia (CLL). This trial was designed to compare chemoimmunotherapy with chemotherapy alone in patients with previously treated CLL.

UR - https://www.scopus.com/pages/publications/77950478885

U2 - 10.1200/JCO.2009.26.4556

DO - 10.1200/JCO.2009.26.4556

M3 - Journal article

C2 - 20194844

VL - 28

SP - 1756

EP - 1765

JO - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology

IS - 10

ER -

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater